Horizon Therapeutics plc Announces Agenda for Virtual R&D Day for Investors and Analysts on Sept. 29, 2021
Horizon Therapeutics plc (NASDAQ: HZNP) announced its virtual R&D Day for investors and analysts on Sept. 29, 2021, from 9 a.m. to 12:30 p.m. ET. The event will feature discussions on the company's expanded pipeline, including key topics such as Horizon’s vision and strategy and new drug candidates HZN-7734, HZN-4920, and HZN-825. R&D leadership and key opinion leaders will engage in Q&A sessions, highlighting the company’s commitment to addressing critical needs in rare and autoimmune diseases.
- Introduction of new pipeline candidates like HZN-7734 and HZN-4920.
- Engagement with investors through a dedicated R&D Day.
- None.
-- Event Begins at
The virtual event will be held from
Horizon’s R&D Day investor event will cover the following topics:
Horizon’s Vision and Strategy
Horizon’s R&D Strategy
HZN-7734: First and Only Plasmacytoid Dendritic Cell Depleter in Clinical Development
HZN-4920: CD40L Antagonist Designed to Block a Central Pathway Involved in Many Autoimmune and Inflammatory Diseases
HZN-825 LPAR1 Antagonist with Early Signals of Benefit in Fibrotic Diseases, Areas of High Unmet Need
UPLIZNA® (inebilizumab-cdon): Next-Generation B-Cell Depleter with a Novel, Targeted Approach
TEPEZZA® (teprotumumab-trbw): Building Evidence to Help Treat More Patients with Chronic Thyroid Eye Disease (TED)
Closing Remarks
About Horizon
Horizon is focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases. Our pipeline is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, please visit www.horizontherapeutics.com and follow us on Twitter, LinkedIn, Instagram and Facebook.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210923005292/en/
Investors:
Senior Vice President, Investor Relations
investor-relations@horizontherapeutics.com
Executive Director, Investor Relations
investor-relations@horizontherapeutics.com
Executive Vice President, Corporate Affairs & Chief Communications Officer
media@horizontherapeutics.com
Ireland Media:
Gordon MRM
ray@gordonmrm.ie
Source:
FAQ
What is Horizon Therapeutics' R&D Day about on September 29, 2021?
What topics will be covered during Horizon's R&D Day?
How can I attend Horizon Therapeutics' virtual R&D Day?
Who will speak at the Horizon Therapeutics R&D Day?